Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta‐analysis

  title={Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta‐analysis},
  author={X-J Li and Ya-xin Yu and C‐Q. Liu and W. Zhang and Hj Zhang and Bing Yan and L‐Y. Wang and S-Y Yang and S-h Zhang},
  journal={Clinical Endocrinology},
Objectives  Insulin‐sensitizing drugs (ISDs) have been advocated for the long‐term treatment of polycystic ovary syndrome (PCOS). It is therefore important to compare the efficacy and safety of ISDs such as metformin and thiazolidinediones (TZDs) for the treatment of this syndrome. 

Reproductive endocrinology: Metformin or thiazolidinedione therapy in PCOS?

Insulin resistance has a key role in the pathogenesis of polycystic ovary syndrome, a common endocrinopathy that affects young women. Therefore, the use of insulin-sensitizing agents has been studied

Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta‐analysis of randomized controlled trials

Polycystic ovary syndrome is a complex endocrine condition affecting women of reproductive age and is a major risk factor for type 2 diabetes mellitus (T2DM).

Insulin sensitizers in polycystic ovary syndrome.

Improvement of insulin sensitivity may produce several benefits in the treatment of a complex disorder like polycystic ovary syndrome, including a decrease in insulin and androgen levels, improvement of metabolic comorbidities, and, finally, improved ovulation and fertility.

Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews

The quality of evidence supporting the recommendations on treatment of nonreproductive outcomes in PCOS is unknown and the need for further research is unknown.

A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene‐citrate‐resistant polycystic ovary syndrome

Treatment of polycystic ovary syndrome: recent trial results

This review presents the data from trials in polycystic ovary syndrome management and assess the relative benefits of currently available treatments.

Polycystic Ovary Syndrome, A Complex Entity Involving Reproductive and Metabolic Impairments: A Systematic Review.

The issue was the systematization of main data regarding different features of PCOS and stressing its peculiar association with characteristics of metabolic syndrome, main diagnostic criteria and most important therapeutic options, finally contouring an updated general picture ofPCOS.

Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome

Although the effects of 2 types of insulin sensitizer drugs, metformin and pioglitazone, on clinical, metabolic, and endocrine characteristics of women with PCOS are compared, there is a significant amelioration of endocrine and metabolic indices with piog litazone in PCOS patients.

Polycystic Ovarian Syndrome: Metformin or Thiazolidinediones for Cardiovascular Risk Reduction?

Clinicians should systematically screen women with diabetes for PCOS and direct appropriate treatment at minimizing related risks based on evidence linking PCOS to diabetes and increased CV risks.

Alternatives to Metformin for Patients with PCOS.

Compared with placebo, thiazolidinediones (TZDs) decrease systolic blood pressure and fasting blood glucose and insulin levels while improving menstrual irregularities in women with PCOS. Metformin



The role of metformin in the treatment of polycystic ovary syndrome (PCOS).

Metformin, an insulin-sensitizing agent, has been proven to be of clinical usefulness both in the short-term aiding of infertility treatments and, potentially, in the prevention of the long-term sequelae for patients with PCOS.

Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome

Treatment will reduce the mean IR in overweight women with polycystic ovarian syndrome and it is not known if the IR variability is also reduced.

Metformin therapy in women with polycystic ovary syndrome

Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?

There is strong evidence supporting the use of metformin as a primary ovulatory agent in women with PCOS and novel evidence suggests that insulin sensitizers may also play a role in reducing the risk of early pregnancy loss.

The Role of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome

Current data support the use of insulin sensitizers, along with lifestyle measures and/or other agents, in women with PCOS, especially in the presence of insulin- or clomifene-resistance.

Drug Insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal

  • A. Dunaif
  • Medicine, Biology
    Nature Clinical Practice Endocrinology &Metabolism
  • 2008
There is, furthermore, no evidence to support the use of metformin during pregnancy to prevent spontaneous abortions or gestational diabetes mellitus in women with PCOS, and there is no evidence that they provide long-term health benefits in PCOS.

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.

This review attempts to cover the spectrum of metformin's cellular actions in different tissues and to summarize the current literature regarding the potential medical value of this medication in PCOS.

Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome.

Although both standard and novel treatments were addressed in the present review, special attention was paid to the evidence in support of the recent introduction of insulin-sensitizing agents in the management of anovulatory woman with CC-resistant PCOS.

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

Metformin is an effective treatment for anovulation in women with polycystic ovary syndrome and its choice as a first line agent seems justified, and there is some evidence of benefit on variables of the metabolic syndrome.